Revisiting Valuation Multiples for Cannabis Companies
Recreational cannabis is close to being legalized in Canada, and producers are running at full bore to capture a piece of the market.
What Analysts Estimate for Cannabis Companies’ Earnings Margins
Let’s now look at how capacity expansion could translate into cannabis companies’ margins.
National Access Cannabis to Get Cannabis from CannaRoyalty
Last week, National Access Cannabis signed a binding term sheet with CannaRoyalty (CRZ) to carry the latter’s products in its stores across Canada.
How Canopy Growth Is Preparing for Legalized Cannabis
During 3Q18, Canopy Growth increased its inventory and biological assets to a value of 108.3 Canadian dollars from 56 million Canadian dollars in 3Q17.
MedReleaf Stock Rises on Aurora Cannabis Acquisition
Today, Aurora Cannabis (ACB)(ACBFF) announced that it agreed to acquire all of MedReleaf’s (MEDFF) outstanding common shares for about 3.2 billion Canadian dollars.
Aurora Cannabis Stock Rises 5.8% on Investment in CTT
On May 22, Aurora Cannabis acquired a 9.1% ownership interest in CTT Pharmaceutical Holdings through a private placement.
How Cannabis Stocks’ Valuations Looked Last Week
The forward EV-to-sales (enterprise value to sales) ratio for the cannabis sector hit a low point in April.
How Aurora Cannabis and MedReleaf Stack Up in Cannabis Sector
Cannabis companies are on an acquisition spree, and companies have made vertical and horizontal acquisitions within the industry.
Canopy Growth Rose 10% Yesterday: Why?
Yesterday, April 30, Canopy Growth (WEED) rose 10% and closed the day at $30.10 Canadian.
Exploring Canopy Growth’s Acquisitions
Canopy Growth (WEED) has been aggressively pursuing its expansion strategy to capture the recreational cannabis market in Canada.
March Analyst Ratings and Price Targets for Aphria
Aphria (APHQF) was among the worst performers this year with a loss of 34% YTD (year-to-date).
Why GMP Securities Is Bullish on Canopy Growth
Last week, GMP Securities analyst Martin Landry maintained a “buy” recommendation on the stock with a price target of 40 Canadian dollars.
How Analysts View Canopy Growth
As of March 22, the consensus analyst mean rating on Canopy Growth was 2.6, which remained unchanged from the previous month.
Digging into Aphria’s Cost of Production
In this part of the series, we’ll discuss how Aphria’s (APHQF) production costs have evolved in the last four quarters.
Comparing Major Cannabis Players’ Prices and Cost Structures
Selling prices and per-gram production costs for cannabis will likely be defining factors in the success of Canadian cannabis producers.
Analysts’ Revenue Estimate Revisions for Cannabis Stocks in March
Cannabis producers’ (HMLSF) sales are expected to rise on expectations of their capturing the recreational cannabis market.
Shoppers Drug Mart Makes Supply Deal with Aurora Cannabis
Last week, Shoppers Drug Mart entered a supply agreement with Aurora Cannabis (ACB)(ACBFF) for medical cannabis.
What Cronos Group’s Listing on the NASDAQ Global Market Means
With the elevation of its listing to the NASDAQ Global Market from the NASDAQ International Designation program, Cronos Group’s (PRMCF) management believes…
Why Cannabis Stock Cronos Group Surged 11% Yesterday
On February 26, cannabis company (HMMJ) Cronos Group (MJN)(PRMCF) surged almost 10.8%.
What Happened in the Cannabis Sector Last Week
Supply agreement with Sunniva With recreational cannabis set to become legal in Canada in mid-2018, Canopy Growth (WEED) continued to make developments to meet the anticipated demand with yet another announcement last week. On February 21, Canopy Growth signed a definitive agreement with Sunniva to purchase up to 90 tons of dried cannabis over two years. The […]
Why Cannabis Stock Canopy Growth Surged 12% Yesterday
The Investment Industry Regulatory Organization of Canada imposed a trading halt on Canopy Growth at 4:11 PM EST on February 16, 2018.
A Look at 2 New Marijuana ETFs that Debuted Last Week
While marijuana stocks (MJX) ended in the negative territory week-over-week last week, two new marijuana sector-specific ETFs debuted.
How Canopy Growth’s Margins Looked in 3Q18
During 3Q18, Canopy Growth reported a non-GAAP (generally accepted accounting principles) gross margin of 58% of sales.
What Were Canopy Growth’s 3Q18 Sales Drivers?
Sales volume, mix, and selling prices are key drivers for Canopy Growth’s (WEED) sales as well as for companies (HMLSF) such as Aphria (APHQF), Aurora Cannabis (ACBFF), and MedReleaf (MEDFF).